Alpha-galactosylceramide is an Effective Mucosal Adjuvant for Repeated Intranasal or Oral Delivery of HIV Peptide Antigens

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2009 Feb 10

PMID 19200849

Citations 38

Authors

Amy N Courtney

Pramod N Nehete

Bharti P Nehete

Prakash Thapa

Dapeng Zhou

K Jagannadha Sastry

Affiliations

Soon will be listed here.

Abstract

Mucosal delivery of vaccines against sexually transmitted pathogens is important to elicit strong immune responses at biologically relevant sites. However, inclusion of appropriate adjuvants is essential to overcome the inherent mucosal tolerance. We present evidence in support of the effectiveness of co-administering alpha-galactosylceramide (alpha-GalCer) as an adjuvant with a CTL-inducing HIV envelope peptide, via either oral or intranasal route, to prime antigen-specific immune responses in multiple systemic and mucosal compartments. Contrary to the known potential of repeated parenteral dosing with alpha-GalCer to induce NKT cell anergy that could compromise adoptive immunity development, we have observed that two and three doses delivered by the intranasal or oral route were more efficient in priming broader antigen-specific immune responses. These results demonstrate the effectiveness of alpha-GalCer as adjuvant for repeated intranasal or oral administration of vaccines for protection against mucosally transmitted pathogens.

Citing Articles

A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome.

Hammond T, Purbhoo M, Kadel S, Ritz J, Nikiforow S, Daley H Nat Commun. 2024; 15(1):974.

PMID: 38321023 PMC: 10847411. DOI: 10.1038/s41467-024-44905-z.

Oral administration of DNA alginate nanovaccine induced immune-protection against Helicobacter pylori in Balb/C mice.

Kaveh-Samani A, Dalali S, Kaviani F, Piri-Gharaghie T, Doosti A BMC Immunol. 2024; 25(1):11.

PMID: 38310250 PMC: 10838413. DOI: 10.1186/s12865-024-00602-6.

Non-Invasive Vaccines: Challenges in Formulation and Vaccine Adjuvants.

Han S, Lee P, Choi H Pharmaceutics. 2023; 15(8).

PMID: 37631328 PMC: 10458847. DOI: 10.3390/pharmaceutics15082114.

Recent Developments in Oral Delivery of Vaccines Using Nanocarriers.

Zafar A, Arshad R, Rehman A, Ahmed N, Akhtar H Vaccines (Basel). 2023; 11(2).

PMID: 36851367 PMC: 9964829. DOI: 10.3390/vaccines11020490.

Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines.

Ou B, Yang Y, Lv H, Lin X, Zhang M BioDrugs. 2023; 37(2):143-180.

PMID: 36607488 PMC: 9821375. DOI: 10.1007/s40259-022-00575-1.

References

Simmons C, Mastroeni P, Fowler R, Ghaem-Maghami M, Lycke N, Pizza M . MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J Immunol. 1999; 163(12):6502-10. View

Fujii S, Shimizu K, Hemmi H, Steinman R . Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol Rev. 2007; 220:183-98. DOI: 10.1111/j.1600-065X.2007.00561.x. View

Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman R . Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med. 2003; 198(2):267-79. PMC: 2194082. DOI: 10.1084/jem.20030324. View

Stevceva L, Ferrari M . Mucosal adjuvants. Curr Pharm Des. 2005; 11(6):801-11. DOI: 10.2174/1381612053381846. View

Casement K, Nehete P, Arlinghaus R, Sastry K . Cross-reactive cytotoxic T lymphocytes induced by V3 loop synthetic peptides from different strains of human immunodeficiency virus type 1. Virology. 1995; 211(1):261-7. DOI: 10.1006/viro.1995.1399. View

Ji H, Wang T, Chen C, Pai S, Hung C, Lin K . Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther. 1999; 10(17):2727-40. DOI: 10.1089/10430349950016474. View

Fujii S, Shimizu K, Kronenberg M, Steinman R . Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol. 2002; 3(9):867-74. DOI: 10.1038/ni827. View

Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A . Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol. 2003; 77(21):11708-17. PMC: 229357. DOI: 10.1128/jvi.77.21.11708-11717.2003. View

Sastry K, Nehete P, Venkatnarayanan S, Morkowski J, Platsoucas C, Arlinghaus R . Rapid in vivo induction of HIV-specific CD8+ cytotoxic T lymphocytes by a 15-amino acid unmodified free peptide from the immunodominant V3-loop of GP120. Virology. 1992; 188(2):502-9. DOI: 10.1016/0042-6822(92)90504-i. View

10.

Felix A, MERRIFIELD R . Azide solid phase peptide synthesis. J Am Chem Soc. 1970; 92(5):1385-91. DOI: 10.1021/ja00708a046. View

11.

Lomada D, Gambhira R, Nehete P, Guhad F, Chopra A, Peterson J . A two-codon mutant of cholera toxin lacking ADP-ribosylating activity functions as an effective adjuvant for eliciting mucosal and systemic cellular immune responses to peptide antigens. Vaccine. 2004; 23(4):555-65. DOI: 10.1016/j.vaccine.2004.05.039. View

12.

Veazey R, Demaria M, Chalifoux L, Shvetz D, Pauley D, Knight H . Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science. 1998; 280(5362):427-31. DOI: 10.1126/science.280.5362.427. View

13.

Moyle P, McGeary R, Blanchfield J, Toth I . Mucosal immunisation: adjuvants and delivery systems. Curr Drug Deliv. 2005; 1(4):385-96. DOI: 10.2174/1567201043334588. View

14.

Li Q, Duan L, Estes J, Ma Z, Rourke T, Wang Y . Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature. 2005; 434(7037):1148-52. DOI: 10.1038/nature03513. View

15.

Holmgren J, Czerkinsky C . Mucosal immunity and vaccines. Nat Med. 2005; 11(4 Suppl):S45-53. DOI: 10.1038/nm1213. View

16.

Gordon S, Klatt N, Bosinger S, Brenchley J, Milush J, Engram J . Severe depletion of mucosal CD4+ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J Immunol. 2007; 179(5):3026-34. PMC: 2365740. DOI: 10.4049/jimmunol.179.5.3026. View

17.

Houghten R . General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Acad Sci U S A. 1985; 82(15):5131-5. PMC: 390513. DOI: 10.1073/pnas.82.15.5131. View

18.

Veazey R, Marx P, Lackner A . The mucosal immune system: primary target for HIV infection and AIDS. Trends Immunol. 2001; 22(11):626-33. DOI: 10.1016/s1471-4906(01)02039-7. View

19.

Ko S, Ko H, Chang W, Park S, Kweon M, Kang C . alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol. 2005; 175(5):3309-17. DOI: 10.4049/jimmunol.175.5.3309. View

20.

Lehner T, Anton P . Mucosal immunity and vaccination against HIV. AIDS. 2003; 16 Suppl 4:S125-32. DOI: 10.1097/00002030-200216004-00017. View